A report examines oncologists' perspectives on personalized medicine, finding that one-third of surveyed oncologists feel 'very familiar' with the concept. The study analyzes the adoption of personalized medicine in oncology, revealing varying views on its tangible benefits versus hype among different practice settings. The report includes insights on genetic testing, treatment regimens, and expectations for the future of personalized medicine in cancer care.

1. PERSONALIZED
MEDICINE’S EFFECT
ON ONCOLOGISTS’
TREATMENT
REGIMENS
A P R I L , 2 0 1 6
P R E V I E W O F

2. REPORT OVERVIEW
WHAT YOU WILL LEARN
One aspect of personalized medicine is certain; it is
complicated. If you happen to have a highly scientific
background, you actually may be able to define the term.
However, if you polled five people very familiar with
personalized medicine, you should expect to hear five
different definitions.
ISR wanted to understand where oncologists stand on the
topic of personalized medicine. We interviewed 101 US-
based, board-certified oncologists to gather their views on
how familiar they are with personalized medicine, how they
are treating patients, what tests are being used and which
will be used more, and how their patient treatment regimens
could evolve in the future.
59
PAGES
101
ONCOLOGISTS
Introduction
SMARTER QUESTIONS SMARTER ANSWERS
MAJOR
SECTIONS:
1. Current Landscape
2. Genetic Tests and
Patient Care
3. Clinical Trial Views
D A T A
C O L L E C T I O N
I N Q 1 , 2 0 1 6
2 0 - M I N U T E
W E B - B A S E D
S U R V E Y
1 0 1 O N C O L O G I S T S
F R O M T H E U N I T E D
S T A T E S
• Oncologists’ familiarity with personalized medicine, and
perceptions related to hype vs. tangible benefit
• Future predictions for the use and benefits related to
personalized medicine in oncology, including potential
hurdles to adoption
• Percentage of patients requesting personalized
medicine vs. percentage of oncologists suggesting
personalized medicine to patients
• Current number of patients treated using genetic tumor
profiling vs. oncologists’ predictions for the number in 3
years
• Oncologists’ interest in conducting clinical trials using
genetic tumor profiling
• What tests oncologists perform, and how the data are
used and stored for use in future clinical trials
F U L L T A B L E O F C O N T E N T S O N N E X T P A G E

3. Introduction
SMARTER QUESTIONS SMARTER ANSWERS
TABLE OF CONTENTS
FOR FULL TABLE OF CONTENTS, PLEASE DOWNLOAD
THE FULL PREVIEW AT:
HTTPS://WWW.ISRREPORTS.COM/REPORTS/PERSONALIZED-
MEDICINES-EFFECT-ON-ONCOLOGISTS-TREATMENT-REGIMENS/

4. Introduction
SMARTER QUESTIONS SMARTER ANSWERS
Introduction
INTRODUCTION
4www.ISRreports.com ©2016 Personalized Medicine’s Effect on Oncologists’ Treatment Regimens
INTRODUCTION
Welcome to ISR’s Personalized
Medicine’s Effect on Oncologists’
Treatment Regimens report�
If you have been in the pharmaceutical
industry for any length of time, it is
likely that you have heard of the term
“personalized medicine�” If you happen
to have a highly scientific background,
you actually may be able to define
the term� However, if you polled five
people very familiar with personalized
medicine, you should expect to hear five
different definitions�
Personalized medicine got a shot in the
arm (maybe a pun) in January 2015 when
President Obama from the United States
indicated during his State of the Union
address that the US would “unveil details
about the Precision Medicine Initiative, a
bold new research effort to revolutionize
how we improve health and treat disease�
Launched with a $215 million investment
in the President’s 2016 Budget, the
Precision Medicine Initiative will pioneer a
new model of patient-powered research
that promises to accelerate biomedical
discoveries and provide clinicians with new
tools, knowledge, and therapies to select
which treatments will work best for which
patients�” Further details on the initiative,
including where the money is going
and what the goals are, can be found at
https://www�whitehouse�gov/the-press-
office/2015/01/30/fact-sheet-president-
obama-s-precision-medicine-initiative�
One aspect of personalized medicine is
certain; it is complicated� For example,
perhaps the posterchild for personalized
medicine is Genentech’s Herceptin� The
Herceptin
HER2Biomarker
Reimbursement
Oncology
Limited
Access
Targeted
Precision
Medicine
InitiativeGenetic
following is a description of Herceptin:
“Herceptin is a monoclonal antibody that
interferes with the HER2/neu receptor� Its
main use is to treat certain breast cancers�
The HER receptors are proteins that are
embedded in the cell membrane and
communicate molecular signals from
S A M P L E P A G E :
INTRODUCTION

5. Introduction
SMARTER QUESTIONS SMARTER ANSWERS
Introduction
CURRENT LANDSCAPE
15www.ISRreports.com ©2016 Personalized Medicine’s Effect on Oncologists’ Treatment Regimens
Oncologist familiarity with
personalized medicine
Without providing a definition of personalized medicine, one-third of US-based oncologists categorize
themselves as being “very familiar, I have a complete understanding of the concepts surrounding
personalized/precision treatments for oncology patients�”
“How familiar are you with the concept(s) surrounding personalized/precision treatments for oncology
patients?” (n=101)
PERSONALIZED MEDICINE’S EFFECT ON ONCOLGISTS’ TREATMENT REGIMENS 1
4
Oncologist familiarity with
personalized medicine
Without providing a definition of personalized medicine, one-third of US-based oncologists categorize
themselves as being “very familiar, I have a complete understanding of the concepts surrounding
personalized/precision treatments for oncology patients.”
“How familiar are you with the concept(s) surrounding personalized/precision treatments for oncology patients?”
(n=101)
After asking the “familiarity” question to begin the survey, respondents were provided with the following
definition:
“For the purposes of this research study, we define personalized medicine as the tailoring of medical
treatment to the individual characteristics of each patient. The approach relies on scientific
breakthroughs in our understanding of how a person's unique molecular and genetic profile makes them
susceptible to certain diseases.”
Very familiar, I have
a complete
understanding of
them
32%
Familiar, have a
basic understanding
of them
44%
I’ve heard of them,
but could not define
them
17%
Have never heard of
them
7%
After asking the “familiarity” question to begin the survey, respondents were provided with the
following definition:
“For the purposes of this research study, we define personalized medicine as the tailoring of medical treatment to
the individual characteristics of each patient. The approach relies on scientific breakthroughs in our understanding
of how a person’s unique molecular and genetic profile makes them susceptible to certain diseases.”
© Industry Standard Research
S A M P L E P A G E :
ONCOLOGIST
FAMILIARITY
WITH
PERSONALIZED
MEDICINE
Without providing a definition
of personalized medicine, one-
third of US-based oncologists
categorize themselves as being
“very familiar, I have a complete
understanding of the concepts
surrounding personalized/
precision treatments for oncology
patients.”
C L O S E R L O O K
There are statistical differences
in how oncologists from
different practice settings
(hospital, university, physician-
owned) responded to this
question.
Learn more in the full report:
www.ISRreports.com
Oncologist familiarity with
personalized medicine
Without providing a definition of personalized medicine, one-third of US-based oncologists categorize
themselves as being “very familiar, I have a complete understanding of the concepts surrounding
personalized/precision treatments for oncology patients.”
“How familiar are you with the concept(s) surrounding personalized/precision treatments for oncology patients?”
(n=101)
Very familiar, I have
a complete
understanding of
them
32%
Familiar, have a
basic understanding
of them
44%
I’ve heard of them,
but could not define
them
17%
Have never heard of
them
7%

6. Introduction
SMARTER QUESTIONS SMARTER ANSWERS
Introduction
CURRENT LANDSCAPE
19www.ISRreports.com ©2016 Personalized Medicine’s Effect on Oncologists’ Treatment Regimens
Total
(n=101)
Rural
(n=11)
C
Suburban
(n=40)
D
Urban
(n=50)
E
Much more hype than tangible benefit
to personalized/ precision oncology
treatments today
13% 9% 18% 10%
Somewhat more hype than tangible
benefit to personalized/ precision
oncology treatments today
35%
55%
E
45%
E
22%
Somewhat more tangible benefit
than hype to personalized/ precision
oncology treatments today
37% 9% 28%
50%
C, D
Much more tangible benefit than hype
to personalized/ precision oncology
treatments today
16% 27% 10% 18%
Statistical differences
Rural oncologists (55%) and suburban oncologists (45%) are more likely than urban oncologists
(22%) to indicate “the healthcare industry will view personalized oncology treatments as somewhat
more hype than tangible benefit” three years from now�
Urban oncologists (50%) are more likely than rural oncologists (9%) and suburban oncologists
(28%) to indicate “the healthcare industry will view personalized oncology treatments as providing
a somewhat more tangible benefit than hype” three years from now�
While not tested for statistical significance, urban oncologists seem more likely to view
personalized medicine as having more tangible benefit (68%) than rural oncologists (38%) and
suburban oncologists (38%)�
S A M P L E P A G E :
STATISTICAL DIFFERENCES
The full data are available in the report, which can be downloaded from www.ISRreports.com.
D A T A I N F U L L R E P O R T

7. Introduction
SMARTER QUESTIONS SMARTER ANSWERS
FOR ADDITIONAL SAMPLE PAGES, PLEASE DOWNLOAD THE FULL
PREVIEW AT:
HTTPS://WWW.ISRREPORTS.COM/REPORTS/PERSONALIZED-
MEDICINES-EFFECT-ON-ONCOLOGISTS-TREATMENT-REGIMENS/

8. TO LEARN MORE: CONTACT US AT INFO@ISRREPORTS.COM OR +1(919)301-0106
Biosimilars &
Biologics
Clinical Trial
Recruitment &
Retention
Commercialization Department
Models &
Structures
Trends &
Technologies
Manufacturing Service
Provider Quality
Benchmarking
CUSTOM RESEARCH
UNDERSTAND YOUR MARKETS
Leverage ISR’s experience and institutional
knowledge to create a fit-for-purpose market
research project that addresses the business
decisions you need to make.
Are you:
• Developing a new product or service?
• Evaluating a new market?
• Targeting a new customer segment?
• Entering a new geography?
• Needing a deeper understanding of your
customer or potential customer base?
UNDERSTAND YOUR CUSTOMERS
Who makes the decisions and in what contexts?
ISR can help you gain a deeper understanding of
your customers’ decision-making units (DMUs) and
decision-making processes (DMPs).
Key Questions Addressed:
• What motivates the purchase decision?
• How are companies, products, solutions, and/or
brands evaluated?
• What factors drive the final buying decision?
• Where are your customers won or lost in the
purchasing process?
• Why were specific opportunities won or lost?
• How do you keep customers engaged and
manage their loyalty over time?
CUSTOM RESEARCH SERVICES
• Investigator Forum
• Brand, Advertising, and Message Testing
• Loyalty Management
• New Product and Service Development
• Competitive Intelligence
• Strategy War Games
• MORE
S O M E T H I N G T O C O N S I D E R
DISTINCTIVE – Receive novel insights
from industry decision-makers on topics
including: service provider quality, patient
recruitment, biosimilars, clinical technology,
manufacturing, clinical operations, and
commercial activities.
UNRESTRICTED – ISR doesn’t sell seats.
Instantly obtain access for all employees within
your organization
AFFORDABLE – Receive access to
ALL reports in ISR’s library, as well as those
released during your subscription period. ISR’s
competitive library pricing equates to the cost of
a few individual report purchases.
LIBRARY ACCESS
SUBSCRIPTION
ISR’s library access subscription provides your entire
organization access to our full library of syndicated
market research reports (100+ titles) plus access
to all reports (~25 per year) released during your
subscription period.
Our research categories include:

9. Introduction
SMARTER QUESTIONS SMARTER ANSWERS
ORDERING INFORMATION
Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services
industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.
For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at
www.ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports.
ABOUT INDUSTRY STANDARD RESEARCH
>> R E G I S T E R N O W
>>Receive $250 instant credit towards any ISR report
>>Earn 10% credit towards all future purchases
>>Receive advanced notifications on ISR’s latest reports and
free resources
SAVE ON THIS,
OR ANY ISR REPORT, BY
CREATING A
FREE ACCOUNT
FOR PRICING AND ORDERING INFORMATION, PLEASE
DOWNLOAD THE FULL PREVIEW AT:
HTTPS://WWW.ISRREPORTS.COM/REPORTS/PERSONALIZED-
MEDICINES-EFFECT-ON-ONCOLOGISTS-TREATMENT-REGIMENS/

10. Introduction
SMARTER QUESTIONS SMARTER ANSWERS
www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions 10
act with confidence
THE ISR DIFFERENCE
Mostly primary
research; always
appropriate for
the topic
One size
fits all; usually
publically
available data
To learn more, visit www.ISRreports.com
ISR’S
REPORTS
THE
COMMON
SYNDICATED
REPORT
VS.
RESEARCH METHODS
ISR’s proprietary data
tools and channels
support fast, high
quality data collection
Struggle to
recurit the right
targets and
enough of them
DATA COLLECTION
Sophisticated screening
ensures genuine
decision-makers
make up respondents
Undisclosed
methodologies
and respondent
demographics
RESPONDENTS
Robust
sample sizes
that instill
confidence
Often insufficient
industry representation
that leaves you
defending results
SAMPLE SIZE
Decades of experience
means more
insights that are
immediately usable
Junior analysts
capable of
reporting
numbers
ANALYSTS
ISR’S HEALTH PANEL
The industry’s fastest growing panel
of health care and pharmaceutical
professionals, with nearly 1,500
members worldwide.
BY
JOB
LEVEL
Director 46%
Manager
29%
C-level 13%
VP 10%
BY
EXPERIENCE
IN YEARS
16-20 years 23%
11-15
years
24%
6-10 years 11%
3-5 years 5%
20+
years
37%
BY
COMPANY
TYPE
Other 6%
Sponsor 78%
CRO 6%
Research
Site 10%